Content overview: “Novo Nordisk's CagriSema Achieves 25% Weight Loss in Phase 3 Trial, Challenging Eli Lilly'”. Novo Nordisk's experimental drug CagriSema delivered a 25% weight loss at its highest dose in a Phase 3 trial, positioning it as a potent rival to Eli Lilly's Zepbound. The trial, which enrolled 3,500 participants with obesity or overweight and at least one comorbidity, compared CagriSema to its individual components—cagrilintide and semaglutide (the active ingredient in Ozempic and Wegovy)—as well as a placebo. At 68 weeks, patients on the highest CagriSema dose lost an average of 25% of their body weight, significantly outpacing the placebo group's 2% loss.
This result surpasses the roughly 20% weight loss seen with Zepbound in similar trials, intensifying competition in the lucrative obesity drug market. CagriSema combines a long-acting amylin analog with a GLP-1 receptor agonist, a dual-action approach that may explain its superior efficacy. The full version stays on the original page, which this listing opens directly.